Globus Medical (NYSE: GMED) announced the acquisition of Higgs Boson Health on Aug. 26, 2026. The deal integrates AI-driven digital tools into the company’s musculoskeletal technology ecosystem. Financial terms were not disclosed.

Higgs Boson Health, based in Durham, NC and incubated out of Duke University, will join Globus Medical to shape patient and provider experiences throughout the full episode of care. The acquisition targets the enhancement of real-time information and surgical intelligence available to healthcare providers.

Strategic Integration

David Paul, Founder and Executive Chairman, stated that Higgs Boson’s teams of software developers and AI scientists will power a seamless digital healthcare environment. The goal is to simplify the patient journey while aiming for 95% good outcomes at 10 years for all musculoskeletal surgeries.

Keith Pfeil, President and Chief Executive Officer, described the move as the next step in building the Globus ecosystem. The technology will form part of the surgical intelligence pillar, integrating outcomes and analytics in a closed-loop manner to foster continuous learning along the full patient journey.

What the Numbers Show

The acquisition focuses on non-financial operational metrics rather than immediate revenue contribution. The stated target of achieving 95% good outcomes at 10 years represents a long-term clinical performance benchmark rather than a short-term financial return indicator.

Globus Medical (NYSE: GMED) delivered a robust second quarter performance in FY26, reporting non-GAAP diluted earnings per share of $1.34, which significantly exceeded analyst consensus estimates of $1.10. The musculoskeletal technology company also saw worldwide net sales rise 5.9% year-over-year to $789.6 million, driven by strong share gains in its US Spine and International Spine businesses. These results underscore effective cost management and margin expansion, leading the firm to raise its full-year non-GAAP EPS guidance to a range of $4.95 to $5.05.

The earnings beat of 21.82% highlights operational leverage realized during the period, while the revenue beat of 0.87% against an estimated $782.8 million indicates sustained market demand. Compared to the prior year, adjusted EPS surged by 55.8% from $0.86, reflecting a substantial improvement in profitability. Revenue grew from $745.3 million in the corresponding quarter last year, demonstrating consistent organic growth despite currency headwinds that resulted in a 5.6% constant currency growth rate.

Financial Highlights

The company’s ability to exceed both earnings and revenue estimates suggests strong market positioning. The significant year-over-year jump in EPS points to improved underlying profitability drivers, even as GAAP net income decreased by 25.3% to $151.6 million, primarily due to a $110.5 million bargain purchase gain recognized in the prior year related to the Nevro acquisition.

Segment Performance and Guidance

US Spine led organizational growth for the fifth consecutive quarter, with US net sales increasing by 3.0% compared to the second quarter of 2025. International net sales showed stronger momentum, rising 18.0% on an as-reported basis and 16.2% on a constant currency basis. Keith Pfeil, President and Chief Executive Officer, noted that share gains across underlying businesses drove the 9% growth excluding Nevro.

Kyle Kline, Chief Financial Officer, attributed the record second-quarter non-GAAP net income to broad-based growth paired with adjusted gross margin expansion of 200 basis points compared to the prior year quarter. The Company reaffirmed its full-year 2026 revenue guidance of $3.18 billion to $3.22 billion but updated its non-GAAP fully diluted EPS guidance upward from the previous range of $4.70 to $4.80.

What the Numbers Show

The divergence between the modest revenue beat (0.87%) and the substantial earnings beat (21.82%) suggests that Globus Medical benefited disproportionately from margin expansion rather than just volume growth. While sales grew steadily at 5.9% year-over-year, the 55.8% surge in adjusted EPS indicates that operating efficiencies or favorable mix shifts played a critical role in boosting bottom-line results. This pattern implies that management has successfully optimized costs or product mix to drive higher profitability even as top-line growth remains moderate.